Liquid BiOpsy, Lung and Colon Cancer in AndaluciA

Enrolling by invitationOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2026

Conditions
Non Small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)
Interventions
DIAGNOSTIC_TEST

xF Tempus assay

"The blood will be collected and sent to Tempus Labs using the standard sample collection kit containing all the necessary elements to guarantee shipment to Tempus Labs. Two Streck tubes with 8.5mL of blood per tube will be sent to Tempus Labs.~The ctDNA isolation and automatic library preparation will be performed using TEMPUS technology (Finkel et al 2021).~The NGS analyses will be developed using the xF Tempus assay. This assay involves a panel with hybrid gene capture that detects actionable oncologic targets in four variant classes: single-nucleotide variants (SNVs), insertions/deletions (indels), copy number variants (CNVs), and gene rearrangements. The NGS sequencing is performed using NovaSeq 6000Dx Sequencing System (Illumina, Inc) equipment, according to Tempus protocols. (Finkel et al 2021)."

Trial Locations (1)

18016

Centre for Genomics and Oncological Research - Pfizer - University of Granada - Andalusian Regional Government (GENyO), Granada

All Listed Sponsors
collaborator

Tempus AI

INDUSTRY

lead

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

OTHER